Trial Profile
An Open, Non-randomize, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2019
Price :
$35
*
At a glance
- Drugs Conbercept (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms LAMP
- Sponsors Chengdu Kanghong Biological Science & Technology; Chengdu Kanghong Biotech
- 07 Apr 2014 New trial record